ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Addressing the Role of PARP Inhibitors in Different Breast Cancer Settings

Jennifer Litton, MD
Published Online:6:39 PM, Tue April 10, 2018

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses her opinion on the use of PARP inhibitors in the field of breast cancer. 

Recent research has led to the availability of numerous drugs for the treatment of HER2+ breast cancer, while PARP inhibitors are only the first targeted therapy for triple-negative breast cancer to meet a primary endpoint. These will be tested in a variety of combinations in the future, Litton predicts. 

PARP inhibitors are currently only being used in cases of metastatic breast cancer with a BRCAgermline mutation. But, Litton notes, we cannot forget about ER+ breast cancer as well, even though there are only a small percent of these patients with a BRCAgermline mutation.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.